Guidewire Software Inc. Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Guidewire Software Inc. Common Stock trades at $165.2 (market cap $13.59B), while State Street SPDR S&P Biotech ETF trades at $147.04 (market cap $10.27B). The key difference: Guidewire Software Inc. Common Stock is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Guidewire Software Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Guidewire Software Inc. Common Stock for 0 Days and State Street SPDR S&P Biotech ETF for 39 Days on average.
| GWRE | XBI | |
|---|---|---|
Market Cap | $13.59B | $10.27B |
Volume | 838,274 | 9,751,587 |
Sector | Technology | Broad Market / Factor |
52-Week High | $254.23 | $169.55 |
52-Week Low | $102.69 | $107.32 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $13.55B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $146.8, down 3.04% today, with a bearish technical signal driven by selling pressure in moving averages. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than diversified healthcare funds.
Outlook remains mixed with neutral analyst consensus but positive sector catalysts. Opportunities include biotech innovation and M&A potential, while risks involve high volatility, regulatory uncertainty, and expense ratios above broader healthcare ETFs. Investors should weigh targeted biotech exposure against sector-wide stability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Guidewire Software Inc. develops InsuranceSuite Cloud, a software platform used by property and casualty insurers for policy administration, billing, and claims processing.
Read more on GWRE →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →